Aurobindo’s CuraTeQ Withdraws European Biosimilars – But They Will Be Back
EMA Refiling Expected After Filgrastim And Pegfilgrastim Applications Withdrawn
Aurobindo’s CuraTeQ has withdrawn EMA filings for its filgrastim and pegfilgrastim biosimilars over inspection timing issues – but expects to refile the products as it works towards obtaining the necessary EU GMP certification.
